Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Journal.
Press releases published on October 22, 2025
NorthWest Copper Announces Results of 2025 AGM
TORONTO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- NorthWest Copper Corp. (“NorthWest” or the “Company”) (TSXV: NWST) is pleased to announce the results of voting at its Annual General Meeting of Shareholders (“AGM”) held October 21, 2025. Shareholders voted in …
ParaZero Secures Significant Purchase Order for Airobotics’ Autonomous Defense Drones, Strengthening Position in Booming Drone Defense Market
Kfar Saba, Israel, Oct. 22, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) …
Gilat to Report Third Quarter 2025 Results on Wednesday, November 12th
PETAH TIKVA, Israel, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (NASDAQ: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions and services, today announced that it will release its third quarter 2025 …
Mutuum Finance (MUTM) Completes Phase 1 of Roadmap, Begins Development of DeFi Lending Protocol
Dubai, UAE, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) continues to gain traction across the crypto market as it reaches another major milestone in its journey toward becoming one of the most promising new DeFi projects of 2025. The Ethereum- …
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera’s dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agreement includes 1) an upfront payment of $3.5 million, 2 …
Electra Therapeutics Announces First Patients Dosed in the SURPASS Phase 2/3 Pivotal Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
The SURPASS study is enrolling patients at research sites across the U.S. and Europe ELA026 targets signal regulatory proteins (SIRP) as a novel approach to treating the life-threatening hyperinflammatory pathology of sHLH SOUTH SAN FRANCISCO, Calif., Oct. …
Electra Therapeutics Receives FDA Breakthrough Therapy and EMA Priority Medicines Designations for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
ELA026 has demonstrated promising potential as a frontline treatment for patients with sHLH, a hyperinflammatory disease with high mortality and significant unmet medical need Electra has initiated the SURPASS global pivotal trial evaluating ELA026 in …
Electra Therapeutics Announces $183 Million Series C Financing to Advance First-in-Class SIRP-Targeted Therapies for Immune Disorders and Cancer
Proceeds will fund a global pivotal trial of lead product candidate, ELA026, as a frontline treatment for secondary hemophagocytic lymphohistiocytosis (sHLH) Financing will also support indication expansion of ELA026 in hematologic cancers and advance …
B2PRIME Welcomes Emanuel Georgouras as CRO to Drive Institutional Growth and Revenue Strategy
DUBAI, United Arab Emirates, Oct. 22, 2025 (GLOBE NEWSWIRE) -- B2PRIME Group, a global financial services provider for institutional and professional clients, has announced the appointment of Emanuel Georgouras as its new Chief Revenue Officer (CRO). The …